STK15 rs2273535 polymorphism and cancer risk: A meta-analysis of 74,896 subjects

Xu, Lei; Zhou, Xin; Jiang, Feng; Xu, Lin; Yin, Rong

doi:10.1016/j.canep.2013.10.008

Cited by 13 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that subjects with Phe/Ile genotype or at least one Phe allele had a significant reduced risk to breast cancer in Malaysian Chinese women even after Bonferroni correction, suggesting that it can be act as a strong protective biomarker for breast cancer in the population. This finding was similar to recent meta-analysis studies claiming that the Ile allele was an increase risk factor for breast cancer (Qin et al, 2013;Tang et al, 2013;Dai et al, 2014;Guo et al, 2014;Xu et al, 2014;Qin et al, 2015). In Malaysia, Malaysian Chinese women has the highest breast cancer incidences when compared to other ethnic groups (Leong et al, 2007;Pathy et al, 2011), and it is yet to clarify that the role of genetic abnormality contribute to the high incidence rate in this ethnic.…”

Section: 647 Association Of Cyp2e1 Stk15 and Xrcc1 Polymorphisms Wisupporting

confidence: 76%

Association of CYP2E1, STK15 and XRCC1 Polymorphisms with Risk of Breast Cancer in Malaysian Women

Chong

Goh²,

See³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Breast cancer is the most common type of cancer affecting Malaysian women. Recent statistics revealed that the cumulative probability of breast cancer and related deaths in Malaysia is higher than in most of the countries of Southeast Asia. Single nucleotide polymorphisms (SNPs) in CYP2E1 (rs6413432 and rs3813867), STK15 (rs2273535 and rs1047972) and XRCC1 (rs1799782 and rs25487) have been associated with breast cancer risk in a meta-analysis but any link in Southeast Asia, including Malaysia, remained to be determined. Hence, we investigated the relationship between these SNPs and breast cancer risk among Malaysian women in the present case-control study. Materials and Methods: Genomic DNA was isolated from peripheral blood of 71 breast cancer patients and 260 healthy controls and subjected to polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Results: Our study showed that the c1/c2 genotype or subjects with at least one c2 allele in CYP2E1 rs3813867 SNP had significantly increased almost 1.8-fold higher breast cancer risk in Malaysian women overall. In addition, the variant Phe allele in STK15 rs2273535 SNP appeared to protect against breast cancer in Malaysian Chinese. No significance association was found between XRCC1 SNPs and breast cancer risk in the population. Conclusions: This study provides additional knowledge on CYP2E1, STK15 and XRCC1 SNP impact of risk of breast cancer, particularly in the Malaysian population. From our findings, we also recommend Malaysian women to perform breast cancer screening before 50 years of age.Keywords: Breast cancer -CYP2E1 -Malaysian women -single nucleotide polymorphisms -STK15 -XRCC1

show abstract

Section: 647 Association Of Cyp2e1 Stk15 and Xrcc1 Polymorphisms Wisupporting

confidence: 76%

Association of CYP2E1, STK15 and XRCC1 Polymorphisms with Risk of Breast Cancer in Malaysian Women

Chong

Goh²,

See³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Of the 96 articles that were initially identified in the search strategy, 80 studies were removed, including 3 duplicates, 77 studies during the title/abstract review, and 5 studies during the full-text review (Ewart-Toland et al, 2005;Couch et al, 2007;Qin et al, 2013;Tang et al, 2013;Xu et al, 2013) (Figure 1). Eleven studies satisfied all of the criteria and were included in this report (Dai et al, 2004;Egan et al, 2004;Sun et al, 2004;Lo et al, 2005;Cox et al, 2006;Fletcher et al, 2006;Tchatchou et al, 2007;Vidarsdottir et al, 2007;2010;Ruan et al, 2011;Shi et al, 2011).…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

The AURKA Gene rs2273535 Polymorphism Contributes to Breast Carcinoma Risk - Meta-analysis of Eleven Studies

Guo

Feng²,

Xia³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Aurora A is overexpressed in many adult tumors including bladder, breast, lung, and head and neck cancers (1)(2)(3)(4); as well as pediatric malignancies (5)(6)(7)(8). The Aurora A kinase gene (AURK) has 2 common polymorphisms; the phe31Ile polymorphism, which alters the kinase function and is associated with tumorigenesis or advanced cancers (9,10); and the Va571Ile polymorphism, which in combination with phe31IIe may be associated with an increased risk of cancer-or treatment-related adverse events (11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Mossé

Fox

Teachey

et al. 2019

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816). Patients and Methods: Alisertib (80 mg/m 2 /dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1 Ã 28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle. Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 mmol/L, exceeding the 1 mmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed. Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving singleagent alisertib was less than 5%.

show abstract

STK15 rs2273535 polymorphism and cancer risk: A meta-analysis of 74,896 subjects

Cited by 13 publications

References 46 publications

Association of CYP2E1, STK15 and XRCC1 Polymorphisms with Risk of Breast Cancer in Malaysian Women

Association of CYP2E1, STK15 and XRCC1 Polymorphisms with Risk of Breast Cancer in Malaysian Women

The AURKA Gene rs2273535 Polymorphism Contributes to Breast Carcinoma Risk - Meta-analysis of Eleven Studies

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Contact Info

Product

Resources

About